Purolite, an Ecolab company and manufacturer of synthetic and agarose-based bioprocessing resins and Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Praesto CH1.
This latest innovation, which was developed for commercialisation by Purolite as part of a multi-year strategic partnership with Repligen, combines Purolite’s patented Jetted beads manufacturing process with Repligen’s leading ligand technology to address previously unmet challenges in specialised mAb purification.
The new CH1 purification resin builds on the success of Purolite’s current protein A resin portfolio, demonstrating high selectivity for antibodies and related fragments containing the human CH1 domain.
This allows for the capture of bispecific antibodies and antibody fragments, as well as the removal of mis-paired species, providing an effective alternative for the purification of antibody variants when Protein A resins are not suitable.
Praesto CH1 delivers high productivity and a lower cost of goods to the bioprocessing market.
Purolite’s Vice President of Research and Development, Jennifer Sorrells, said: “The launch of Praesto CH1 represents the latest offering in Purolite’s growing innovation toolbox for the purification of biologics. Our strategic partnership with Repligen brings leading technologies together to unlock new purification strategies that address our customers’ increasingly diverse biotherapeutic molecules, and the unique purification challenges that these can present."
The announcement of Purolite’s latest resin innovation reinforces the company’s commitment to product expansion and innovation and follows news of its investment in a new bioprocessing production facility based in Landenberg, PA.
The new production facility will be Purolite’s fourth location in Pennsylvania.
